Medical Condition

lung cancer

Total Trials

32

Recruiting Now

32

Trial Phases

Phase 2, Phase 1, Phase 1, Phase 2

Lung cancer research has been transformed by precision medicine, with EGFR, ALK, ROS1, KRAS G12C, and MET exon 14 alterations now serving as key targets for approved therapies. Clinical trials focus on identifying new actionable mutations, overcoming acquired resistance mechanisms, and combining targeted therapies with immunotherapy to deepen and prolong responses.

Trials investigate EGFR exon 20 insertion inhibitors, KRAS G12C inhibitors, bispecific antibodies, combination PD-1/CTLA-4 blockade, and consolidation immunotherapy after chemoradiation for locally advanced disease. Early detection studies using liquid biopsy and low-dose CT screening are also expanding.

Most trials require tissue or liquid biopsy for molecular profiling before enrollment to match patients to targeted therapies.

Frequently Asked Questions — lung cancer Clinical Trials

How many clinical trials are currently recruiting for lung cancer?

ClinicalMetric currently tracks 32 actively recruiting clinical trials for lung cancer, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 32. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for lung cancer?

lung cancer research spans Phase 1 (2 trials), Phase 2 (7 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a lung cancer clinical trial?

Eligibility criteria for lung cancer trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Top Sponsors

Shanghai Pulmonary Hospital, Shanghai, China 2 trials

Massachusetts General Hospital 2 trials

UNICANCER 1 trial

Jiayuan Sun 1 trial

Johns Hopkins University 1 trial

lung cancer

Frequently Asked Questions — lung cancer Clinical Trials

Recruiting Clinical Trials

Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)

Transthoracic vs Transbronchial Cryoablation for Early-stage Peripheral Lung Cancer

Full-Field Optical Coherence Tomography (FFOCT) for Evaluation of Bronchoscopic Small Biopsy Specimens

The Cardiac Stress and Electrocardiographic Changes Caused by Lung Cancer Surgery

Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression

Molecular and Genetic Analysis of Lung Cancer

MRD Monitoring in Lung Cancer After Resection

Research on Building and Application of Internet-based Home Pre-rehabilitation Model for Lung Surgery Patients.

EXoPERT EMERALD Clinical Study

Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury

Study on the Diagnosis of Ground-glass Lung Cancer by Microwave Ablation Combined With Puncture Biopsy

Plasma Metabolomics as a Tool to Distinguish PET-positive Malignant From PET-positive Benign Nodules

Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis

Pulmonary Rehabilitation in Advanced Lung Cancer Survivors

Pan-Canadian Lung Cancer Observational Study (PALEOS)

Biomarkers for Clinical Classification and Outcomes of Immune Checkpoint Inhibitor-Related-Related Myocarditis in Lung Cancer

Lung Cancer Screening of Family Members of Patients With Mutation-Driven Lung Cancer

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors

Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Augmented Endobronchial Ultrasound (EBUS-TBNA) With Artificial Intelligence

Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors

Observational Study Evaluate Pathology Practice Use Artificial Intelligence in Patient Suspected Lung and Breast Cancer

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

CARE Tool Study Aim 3

Increasing Lung Cancer Screening Uptake Among Emergency Department Patients

DOLCE: Determining the Impact of Optellum's Lung Cancer Prediction Solution

Detection of Genetic Markers of Lung Cancer

Prevention of Smoking Related Diseases

An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting